AVTR
Avantor, Inc.
AVTR's fundamentals are mixed, but it looks cheap: trading at 31x earnings, below its usual 42x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AVTR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
AVTR's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AVTR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $15.62 | — |
| Cheap | 21x | $10.56 | -32% |
| Current | 31x | $15.62 | — |
| Fair | 41x | $20.70 | +33% |
| Expensive | 96x | $47.90 | +207% |
Historical ranges are pointers, not guarantees.
AVTR's PE is in its fair range at 31x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AVTR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
AVTR has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AVTR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.88 | +75% |
| Q3 2026 | $0.50 | +$0.63 |
| Q2 2026 | -$0.84 | -185% |
| Q1 2026 | -$0.81 | -178% |
| Q4 2025 | -$0.78 | -175% |
| Q3 2025 | -$0.13 | -129% |
| Q2 2025 | $0.99 | +87% |
| Q1 2025 | $1.04 | +174% |
| Q4 2024 | $1.04 | +121% |
AVTR has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AVTR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.7B | +4.6% |
| Q2 2026 | $1.7B | +0.5% |
| Q1 2026 | $1.6B | 0% |
| Q4 2025 | $1.7B | -1.4% |
| Q3 2025 | $1.6B | -5.3% |
| Q2 2025 | $1.7B | -1.1% |
| Q1 2025 | $1.6B | -5.9% |
| Q4 2024 | $1.7B | -2.1% |
AVTR's revenue has held roughly level: $1.7B last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.2% | +48 points |
| Q2 2026 | 7.2% | -0.5 points |
| Q1 2026 | 6.3% | -3 points |
| Q4 2025 | 7.6% | -30 points |
| Q3 2025 | -40% | -47 points |
| Q2 2025 | 7.7% | -2.7 points |
| Q1 2025 | 9.3% | +0.6 points |
| Q4 2024 | 38% | +27 points |
AVTR has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AVTR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AVTR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $156.2M | -9% |
| Q2 2026 | $140.6M | +13% |
| Q1 2026 | $25.2M | -69% |
| Q4 2025 | $117.2M | -20% |
| Q3 2025 | $171.7M | -16% |
| Q2 2025 | $124.8M | -47% |
| Q1 2025 | $81.3M | -24% |
| Q4 2024 | $145.8M | -27% |
AVTR's free cash flow has been positive every quarter for seven years: $439M over the past year, down 16% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AVTR on cash flow, with more consistent year-over-year improvement.
AVTR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +3.7M shares |
| 1 year | -0.1% | -800K shares |
| 3 years | +0.4% | +2.4M shares |
| 5 years | +14% | +82.8M shares |
| Available history | +17% | +99.6M shares |
AVTR has 681M diluted shares, about the same as a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AVTR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AVTR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.6x | Elevated |
| Q2 2026 | 28.9x | High |
| Q1 2026 | 29.1x | High |
| Q4 2025 | 21.8x | High |
| Q3 2025 | 5.4x | High |
| Q2 2025 | 2.6x | Moderate |
| Q1 2025 | 2.5x | Moderate |
| Q4 2024 | 2.6x | Moderate |
AVTR's net debt is about 3.5 years of its operating earnings (EBITDA), down from 5.4 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AVTR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.2 | Neutral |
| Stochastic | 62.4 | Neutral |
AVTR's weekly RSI is 64 (neutral) and its Stochastic is 62 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AVTR PE vs Healthcare Sector
| Metric | AVTR | Sector median | Relative |
|---|---|---|---|
| PE | 31x | 26x | 21% above |
| PE % | 33 | 29 | 4 pts above |
AVTR is trading at 31x earnings, a 21% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AVTR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.9 | 1.7% below |
| 20 week MA | $14.3 | 9.3% above |
| 50 week MA | $11.4 | 37% above |
| 100 week MA | $13.2 | 18% above |
| 200 week MA | $17.8 | 12% below |
AVTR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AVTR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.2 | $27.1 | +49% |
| 2021 | $27.1 | $41.3 | +52% |
| 2022 | $41.3 | $20.5 | -50% |
| 2023 | $20.5 | $22.8 | +11% |
| 2024 | $22.8 | $21.4 | -6.2% |
| 2025 | $21.4 | $11.4 | -47% |
| 2026 YTD | $11.4 | $15.6 | +37% |
AVTR has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.